Trials / Completed
CompletedNCT02955186
Saracatinib and Alcohol Drinking
Fyn Kinase Inhibitors and Alcohol Drinking
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Yale University · Academic / Other
- Sex
- All
- Age
- 21 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the effects of the study medication, saracatinib/AZD0530 (placebo or 125 mg/day) on alcohol drinking behavior in a laboratory setting in which participants are given an initial drink of alcohol followed by the choice to drink up to 12 more drinks over a three-hour period. The investigators hypothesize that saracatinib will reduce craving and number of drinks consumed prior to and after exposure to the initial drink of alcohol and during the three hour drinking period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Saracatinib | Saracatinib 125 mg once per day for 8 days |
| DRUG | Placebos | Placebo once per day for 8 days |
Timeline
- Start date
- 2017-05-09
- Primary completion
- 2019-04-24
- Completion
- 2019-06-07
- First posted
- 2016-11-04
- Last updated
- 2020-11-13
- Results posted
- 2020-11-13
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02955186. Inclusion in this directory is not an endorsement.